129 related articles for article (PubMed ID: 37260251)
21. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
22. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
23. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
le Roux SM; Cotton MF; Myer L; le Roux DM; Schaaf HS; Lombard CJ; Zar HJ
Int J Tuberc Lung Dis; 2013 Jan; 17(1):26-31. PubMed ID: 23146410
[TBL] [Abstract][Full Text] [Related]
24. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
Hanta I; Ozbek S; Kuleci S; Sert M; Kocabas A
Clin Rheumatol; 2007 Nov; 26(11):1867-70. PubMed ID: 17332973
[TBL] [Abstract][Full Text] [Related]
25. Adverse events with isoniazid preventive therapy: experience from a large trial.
Grant AD; Mngadi KT; van Halsema CL; Luttig MM; Fielding KL; Churchyard GJ
AIDS; 2010 Nov; 24 Suppl 5():S29-36. PubMed ID: 21079425
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
Padmapriyadarsini C; Sekar L; Reddy D; Chitra A; Poornagangadevi N; Selvaraj M; Bhavani PK; Mothi SN; Nandagopal K; Vennila S; Tamizhselvan M; Maheshmanisha J; Agarwal U; Rewari BB; Swaminathan S
Indian J Med Res; 2020 Dec; 152(6):648-655. PubMed ID: 34145105
[TBL] [Abstract][Full Text] [Related]
27. Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis: Is it harmful for transplanted liver?
Ghayumi SMA; Shamsaeefar A; Motazedian N; Mashhadiagha A; Sayadi M; Nikeghbalian S; Malekhosseini SA
Transpl Infect Dis; 2022 Aug; 24(4):e13849. PubMed ID: 35579604
[TBL] [Abstract][Full Text] [Related]
28. Treatment of latent tuberculosis infection in HIV infected persons.
Akolo C; Adetifa I; Shepperd S; Volmink J
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD000171. PubMed ID: 20091503
[TBL] [Abstract][Full Text] [Related]
29. Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy.
Kaptan Y; Suner A; Taş MN; Oksel F; Aksu K; Sayiner A
Clin Rheumatol; 2021 Sep; 40(9):3783-3788. PubMed ID: 33745083
[TBL] [Abstract][Full Text] [Related]
30. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
[TBL] [Abstract][Full Text] [Related]
31. Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia.
Mukherjee TI; Hirsch-Moverman Y; Saito S; Gadisa T; Melaku Z; Howard AA
Drug Alcohol Depend; 2019 Nov; 204():107465. PubMed ID: 31499239
[TBL] [Abstract][Full Text] [Related]
32. [Liver damage in treatment of latent tuberculous infection by isoniazid].
Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
Kekkaku; 2006 Nov; 81(11):651-60. PubMed ID: 17154043
[TBL] [Abstract][Full Text] [Related]
33. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
[TBL] [Abstract][Full Text] [Related]
34. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
[TBL] [Abstract][Full Text] [Related]
35. Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam.
Bakari M; Moshi A; Aris EA; Chale S; Josiah R; Magao P; Pallangyo N; Mugusi F; Sandström E; Biberfeld G; Mhalu F; Pallangyo K
East Afr Med J; 2000 Sep; 77(9):494-7. PubMed ID: 12862141
[TBL] [Abstract][Full Text] [Related]
36. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
[TBL] [Abstract][Full Text] [Related]
37. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
38. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
[TBL] [Abstract][Full Text] [Related]
39. Liver injury during antituberculosis treatment: an 11-year study.
Døssing M; Wilcke JT; Askgaard DS; Nybo B
Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment.
Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB
Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
